Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T8330 | BIO-013077-01 | 746667-48-1 | 98% |
|
BIO-013077-01 is a potent TGFbeta family type I receptors antagonist. | ||||
T3636 | (E)-SIS3 | 521984-48-5 | 98% |
|
(E)-SIS3 (SIS3), a selective Smad3 inhibitor, can attenuate TGF-β1-dependent Smad3 phosphorylation and DNA binding. It has no effect on p38 MAPK, Smad2, ERK or P... | ||||
T1449 | Hydrochlorothiazide | 58-93-5 | 98% |
|
Hydrochlorothiazide (HCTZ) is a Thiazide Diuretic. The physiologic effect of hydrochlorothiazide is by means of Increased Diuresis. | ||||
T41245 | Trimethylamine N-oxide | 1184-78-7 | 98% |
|
Trimethylamine N-oxide (TMAO) is a colorless amine oxide produced from choline, betaine, and carnitine via intestinal microbial metabolism that accumulates in ti... | ||||
T24897 | TP0427736 | 864374-00-5 | 98% |
|
TP-0427736 is a novel potent and selective ALK5 inhibitor (IC50: 2.72 nM). P0427736 was 300-fold higher than the inhibitory effect on ALK3. TP0427736 reduces TGF... | ||||
T77019 | Garetosmab | 2097125-54-5 | 98% |
Garetosmab
|
Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cance... | ||||
T76941 | Carotuximab | 1268714-50-6 | 98% |
Carotuximab
|
Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD10... | ||||
T76863 | Elezanumab | 1791416-49-3 | 98% |
|
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 ... | ||||
T76858 | Ascrinvacumab | 1463459-96-2 | 98% |
Ascrinvacumab
|
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has ... | ||||
T76774 | Ponsegromab | 2368950-15-4 | 98% |
Ponsegromab
|
Ponsegromab (PF 06946860) is a selective and effective humanized anti-GDF15 antibody inhibitor. Ponsegromab has anti-cachexic activity by binding to GDF15 to pre... | ||||
T76681 | Fresolimumab | 948564-73-6 | 98% |
Fresolimumab
|
Fresolimumab (GC1008) is a specific human anti-transforming growth factor β monoclonal antibody that binds to the active forms of human TGFβ1, TGFβ2, and TGFβ3 a... | ||||
T20319 | Pentabromophenol | 608-71-9 | 98% |
|
Pentabromophenol (NSC-5717) suppressed TGF-β response by accelerating the turnover rate of TGF-β receptors. | ||||
T60644 | SJ000063181 | 945189-68-4 | 98% |
|
SJ000063181 is a potent activator of BMP signaling, exhibiting an EC50 of ≤1 μM. It serves as a valuable chemical probe for BMP signaling analysis, owing to its ... | ||||
T7676 | LSKL, Inhibitor of Thrombospondin TSP-1 acetate | T7676 |
|
|
LSKL, Inhibitor of Thrombospondin TSP-1 acetate is activation of TGF-β . | ||||
T5197 | BIBF0775 | 334951-90-5 |
|
|
BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM). | ||||
T61301 | Chromenone 1 | 1639929-29-5 | 100% |
|
Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP). Chromenone 1 induces a pronounced, kinase-independent, negative TGFβ feedbac... | ||||
T11052L | Disitertide acetate | 95.11% |
|
|
Disitertide acetate (P144 acetate) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its rec... | ||||
T36680 | SM1-71 | 2088179-99-9 | 96% |
|
SM1-71 is a potent multi-targeted acrylamide-modified TAK1 inhibitor that inhibits MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3,... | ||||
T1748 | Kartogenin | 4727-31-5 | 96.25% |
|
Kartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes. | ||||
T2510 | Galunisertib | 700874-72-2 | 97.09% |
|
Galunisertib (LY2157299) is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity. |